As part of the pre-briefings ahead of the Google Cloud Next 2025 conference last week and then during the keynote address, ...

Google Cloud's commitment in infrastructure such as TPUs reflects the scale of investment required to maintain competitive ...

Ironwood Pharmaceuticals (NASDAQ:IRWD) announced Monday it has decided to evaluate strategic alternatives for the company ...

The FDA will require an additional Phase III trial for apraglutide, the company's candidate for short bowel syndrome.

Google has unveiled a new AI processor, the seventh generation of its custom TPU architecture. The chip, known as Ironwood, ...

Shares in Ironwood Pharma fell by a third after it revealed that the FDA is insisting on a new phase 3 trial of its short ...

Craig-Hallum downgraded Ironwood (IRWD) to Hold from Buy with a price target of $1, down from $7, as the risk-reward has changed following the ...

Ironwood Pharmaceuticals has been left considering its options after the FDA demanded another phase 3 trial before it will consider the biopharma’s long-acting GLP-2 analog for approval.

The 'Ironwood' chip marks a major shift in focus for Google, as performance and efficiency are taking a backseat.

Ironwood Pharma (IRWD – Research Report) received a Hold rating and price target from Craig-Hallum analyst Chase Knickerbocker today.Stay ...

Ironwood Pharmaceuticals shares sank after the company said it needs to conduct a confirmatory phase 3 trial of proposed short-bowel treatment apraglutide. The stock hit a 52-week low in mid-morning ...